AstraZeneca PLC Files 6-K Shareholding Report

TL;DR

AZN filed a routine 6-K for shareholding info, nothing major to see here.

AI Summary

AstraZeneca PLC filed a Form 6-K on September 25, 2025, reporting its shareholding information as required for foreign issuers. The filing indicates the company is submitting its annual reports under Form 20-F. No specific financial transactions or new developments were detailed in this particular filing.

Why It Matters

This filing is a routine disclosure for foreign issuers like AstraZeneca, providing transparency on shareholding structures and regulatory compliance with the SEC.

Risk Assessment

Risk Level: low — This is a standard, routine filing for a foreign issuer and does not contain new material information that would typically impact risk.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• 001-11960 (company) — SEC File Number
• 20250925 (date) — Filing Date
• Form 6-K (document) — Filing Type
• Form 20-F (document) — Annual Report Form

FAQ

From the Filing

0001654954-25-011107.txt : 20250925 0001654954-25-011107.hdr.sgml : 20250925 20250925132710 ACCESSION NUMBER: 0001654954-25-011107 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250925 FILED AS OF DATE: 20250925 DATE AS OF CHANGE: 20250925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251342488 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a8844a.htm DIRECTOR/PDMR SHAREHOLDING a8844a FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of September 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________       AstraZeneca PLC   INDEX TO EXHIBITS     1. Director/PDMR Shareholding   25 September 2025   Transaction by Person Discharging Managerial Responsibilities   AstraZeneca PLC (the Company) announces that it was notified on 25 September 2025 that Karen Knudsen, Non-Executive Director, had acquired 9 American Depositary Shares (ADSs) in the Company on 9 September 2025, pursuant to the reinvestment of the first interim dividend in respect of the year ending 31 December 2025, paid by the Company on 8 September 2025. Two ADSs are equivalent to one of the Company's ordinary shares of $0.25 each.   Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). 1   Details of the person discharging managerial responsibilities / person closely associated   a) Name   Karen Knudsen 2   Reason for the notification   a)   Position/status   Non-Executive Director b)   Initial notification /Amendment   Initial notification 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   a)   Name   AstraZeneca PLC b)   LEI   PY6ZZQWO2IZFZC3IOL08 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   a